These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 29056013)

  • 61. [Role and mechanism of action of fibroblast growth factor-21 in reducing triglyceride in nonalcoholic fatty liver disease].
    Chen L; Jiang M; Xin Y; Wang J; Liu Y; Jiang X; Xuan S
    Zhonghua Gan Zang Bing Za Zhi; 2016 Feb; 24(2):102-7. PubMed ID: 26983476
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The gamma-glutamyl transpeptidase to platelet ratio for non-invasive assessment of liver fibrosis in patients with chronic hepatitis B and non-alcoholic fatty liver disease.
    Li Q; Lu C; Li W; Huang Y; Chen L
    Oncotarget; 2017 Apr; 8(17):28641-28649. PubMed ID: 28415736
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Evaluation of hepatosteatosis in patients with chronic hepatitis B virus infection.
    Sefa Sayar M; Bulut D; Acar A
    Arab J Gastroenterol; 2023 Feb; 24(1):11-15. PubMed ID: 35688683
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Chronic inflammation involves CCL11 and IL-13 to facilitate the development of liver cirrhosis and fibrosis in chronic hepatitis B virus infection.
    Wong SW; Ting YW; Yong YK; Tan HY; Barathan M; Riazalhosseini B; Bee CJ; Tee KK; Larsson M; Velu V; Shankar EM; Mohamed R
    Scand J Clin Lab Invest; 2021 Apr; 81(2):147-159. PubMed ID: 33528280
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Analysis of clinical and pathological features of chronic hepatitis B with hepatic steatosis].
    Mi YQ; Liu YG; Xu L; Fan JG; Zhang H; Ping L; Shi RF
    Zhonghua Gan Zang Bing Za Zhi; 2009 Nov; 17(11):817-20. PubMed ID: 19958639
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Serum gamma-glutamyltranspeptidase distinguishes non-alcoholic fatty liver disease at high risk.
    Tahan V; Canbakan B; Balci H; Dane F; Akin H; Can G; Hatemi I; Olgac V; Sonsuz A; Ozbay G; Yurdakul I; Senturk H
    Hepatogastroenterology; 2008; 55(85):1433-8. PubMed ID: 18795706
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Abnormal expression of CD44 aggravates liver disease progression in patients with non-alcoholic fatty liver disease accompanied with hepatitis B virus replication].
    Wu XF; Sha CX; Yang JL; Liu Y; Zhou P; Yao DF; Yao M
    Zhonghua Gan Zang Bing Za Zhi; 2021 Nov; 29(11):1083-1088. PubMed ID: 34933427
    [No Abstract]   [Full Text] [Related]  

  • 68. [Value of hydrogen proton magnetic resonance spectroscopy in the determination of liver triglyceride in patients with fatty liver disease and its influencing factors].
    Qu HJ; Wang L; Jin PH; Gao Q; Zhou JX; Song Y; Wang J; Jiang YM; Gong L; Chen GY; Ding JP; Shi JP
    Zhonghua Gan Zang Bing Za Zhi; 2017 Nov; 25(11):858-863. PubMed ID: 29325281
    [No Abstract]   [Full Text] [Related]  

  • 69. [Non-invasive techniques in diagnosis of steatosis and fibrosis in nonalcoholic fatty liver disease].
    Roĭtberg GE; Lazebnik LB; Zvenigorodskaia LA; Sharkhun OO; Ushakova TI; Platonova OE
    Eksp Klin Gastroenterol; 2013; (7):3-9. PubMed ID: 24772867
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Impact of liver steatosis on the curative effect of pegylated interferon-alpha-2a in patients with chronic hepatitis B].
    Xu L; Li P; Shi Q; Mi Y
    Zhonghua Gan Zang Bing Za Zhi; 2015 Feb; 23(2):99-102. PubMed ID: 25880974
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Prevalence of hepatic steatosis in chronic hepatitis B patients and its association with disease severity.
    Lesmana LA; Lesmana CR; Pakasi LS; Krisnuhoni E
    Acta Med Indones; 2012 Jan; 44(1):35-9. PubMed ID: 22451183
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Prevalence and risk factors of hepatic steatosis and its impact on liver injury in Chinese patients with chronic hepatitis B infection.
    Shi JP; Fan JG; Wu R; Gao XQ; Zhang L; Wang H; Farrell GC
    J Gastroenterol Hepatol; 2008 Sep; 23(9):1419-25. PubMed ID: 18853998
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Overexpression of Hepassocin in Diabetic Patients with Nonalcoholic Fatty Liver Disease May Facilitate Increased Hepatic Lipid Accumulation.
    Abdelmoemen G; Khodeir SA; Zaki AN; Kassab M; Abou-Saif S; Abd-Elsalam S
    Endocr Metab Immune Disord Drug Targets; 2019; 19(2):185-188. PubMed ID: 30009716
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease: A cohort study.
    Joo EJ; Chang Y; Yeom JS; Ryu S
    Hepatology; 2017 Mar; 65(3):828-835. PubMed ID: 28035771
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Pathogenesis of non-alcoholic fatty liver disease mediated by YAP.
    Chen P; Luo Q; Huang C; Gao Q; Li L; Chen J; Chen B; Liu W; Zeng W; Chen Z
    Hepatol Int; 2018 Jan; 12(1):26-36. PubMed ID: 29330836
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Post-load insulin resistance is an independent predictor of hepatic fibrosis in virus C chronic hepatitis and in non-alcoholic fatty liver disease.
    Svegliati-Baroni G; Bugianesi E; Bouserhal T; Marini F; Ridolfi F; Tarsetti F; Ancarani F; Petrelli E; Peruzzi E; Lo Cascio M; Rizzetto M; Marchesini G; Benedetti A
    Gut; 2007 Sep; 56(9):1296-301. PubMed ID: 17392334
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Validation of water-fat MRI and proton MRS in assessment of hepatic fat and the heterogeneous distribution of hepatic fat and iron in subjects with non-alcoholic fatty liver disease.
    Hui SCN; So HK; Chan DFY; Wong SKH; Yeung DKW; Ng EKW; Chu WCW
    Eur J Radiol; 2018 Oct; 107():7-13. PubMed ID: 30292275
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Circulating lipocalin 2 is neither related to liver steatosis in patients with non-alcoholic fatty liver disease nor to residual liver function in cirrhosis.
    Meier EM; Pohl R; Rein-Fischboeck L; Schacherer D; Eisinger K; Wiest R; Krautbauer S; Buechler C
    Cytokine; 2016 Sep; 85():45-50. PubMed ID: 27288631
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Analysis of metabolic risk factors for developing nonalcoholic fatty liver in patients with type 2 diabetes mellitus].
    Guo M; Xi G; Yang N; Yao H
    Zhonghua Gan Zang Bing Za Zhi; 2014 Aug; 22(8):631-5. PubMed ID: 25243967
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Hepatic steatosis in chronic hepatitis B patients is associated with metabolic factors more than viral factors.
    Peng D; Han Y; Ding H; Wei L
    J Gastroenterol Hepatol; 2008 Jul; 23(7 Pt 1):1082-8. PubMed ID: 18707599
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.